Steps Forward: Immunoassays for cryptic HDGFL2 flag TDP-43 proteinopathy in diverse disorders. Companies have moved a PET ligand into Phase 1 trials.

A documentary of country legend Glen Campbell's life and “Goodbye Tour” following his diagnosis of Alzheimer's ...

Other Phenotypes Premature death, attributed to hindbrain tauopathy, generally occurs between eight and 12 months (Dutschmann et al., 2010). Premature death is preceded by weight loss, hyperkyphosis, ...

Findings The presence of three copies of chromosome 21, which harbors the amyloid precursor protein (APP) gene, is the most common genetic cause of Alzheimer’s disease. Carriers of this alteration ...

The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...

Today, Biogen and Eisai announced they would terminate the Phase 3 ENGAGE and EMERGE trials of aducanumab for early Alzheimer’s disease. A futility analysis run by an independent data-monitoring ...

If enhancing memory with light and sound seems futuristic, then welcome to the future. Or so some scientists say. Results from four early stage clinical trials on mild Alzheimer’s disease were ...

Researchers have devised a new way to sneak therapeutic cargo across the blood-brain barrier. Into the constant region of a human IgG1 antibody, they slid a domain that latches onto receptors that ...

After months of uncertainty, the hammer fell for Biogen: In a draft decision released January 11, the Centers for Medicare and Medicaid Services proposed to cover the anti-amyloid antibody Aduhelm ...

John Trojanowski was a wonderful leader, wrote Bradley Hyman, Massachusetts General Hospital, Charlestown. “His style was to always push the field to the next level, whether that was in classic ...

Two immunoprecipitation-mass-spectrometry assays came out on top, accurately pegging people who had plaques 83 to 87 percent of the time. The other assays hovered between 64 to 80 percent.

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...